兒童近視控制 8 大迷思
阿托品、OK 鏡、紅光、戶外時間，哪個最有效？

迷思 1 · 「近視只是看不清楚，長大後雷射就好」

近視的本質是眼軸過度拉長（超過 24 mm)。眼軸拉長後，視網膜被往後拖、變薄、可能出現裂孔。即使日後雷射把角膜磨薄（LASIK / SMILE）矯正度數,眼軸長度不會縮短,所有與「眼球太長」相關的併發症仍然存在。

高度近視（度數 ≥ -5.00 D / 500 度，眼軸 ≥ 26 mm）成年後的併發症風險：

• 視網膜剝離 — 高度近視風險增加 5-10 倍
• 青光眼 — 風險增加 2-3 倍
• 近視性黃斑部病變 — 是亞洲不可逆失明的主要原因之一
• 白內障 — 提早 5-10 年發生

所以兒童近視控制的目標不是「看得清楚」，而是把成年後的最終度數壓在 -5.00 D 以下,降低終身失明風險。

迷思 2 · 「假性近視多休息就會好，不用看醫生」

假性近視（Pseudomyopia)是睫狀肌長時間用眼後痙攣，造成暫時性調節力過強，看遠模糊。但睫狀肌一放鬆就恢復。真性近視（Axial myopia)則是眼軸真的拉長，不可逆。

外觀上兩者完全一樣 — 都是「看遠模糊」。唯一可靠的方法是散瞳後驗光（cycloplegic refraction),通常用 1% Cyclopentolate 點眼後 30-45 分鐘，讓睫狀肌完全放鬆，再驗光。如果散瞳前後度數差很多 → 假性近視為主；如果散瞳後仍有度數 → 真性近視已經形成。

第一次發現孩子看遠模糊就應該立刻就醫,不能觀察。原因：即使是假性近視，也代表眼睛長期過勞；若不介入，很快會變真性近視。台灣國健署建議學齡兒童每年做一次完整視力檢查（含散瞳驗光）。

迷思 3 · 「低濃度阿托品（Atropine)0.01% / 0.05% 哪個好?」

2019 年香港 Yam JC 等人發表的 LAMP 研究（Low-concentration Atropine for Myopia Progression),將 438 位 4-12 歲華人兒童隨機分配到三組，比較三種濃度的低濃度阿托品。第 1 年結果發表在 Ophthalmology 2019，第 2、3 年延伸資料陸續發表。關鍵結論：

解讀建議：

• 近視快速進展（>0.50 D / 年） → 從 0.05% 開始；畏光不耐受可降階。
• 進展緩慢、學齡前 → 可從 0.025% 或 0.01% 試試。
• 停藥反彈（rebound) — ATOM2 研究顯示，高濃度（0.5%）停藥反彈大，但 0.01% 反彈最小。LAMP 第 3 年資料顯示 0.05% 與 0.025% 反彈也很輕。

實務上多數眼科醫師現在從 0.05% 開始，並搭配防曬太陽眼鏡來緩解畏光。

迷思 4 · 「角膜塑型片（OK 鏡）會傷角膜、得感染」

角膜塑型片（Orthokeratology, Ortho-K）是夜戴日取的高透氧硬式隱形眼鏡，睡眠時暫時把角膜中央壓平，白天不戴就能看清楚。研究顯示對近視控制有 40-50% 的減緩效果，機轉是改變周邊視網膜離焦訊號。

感染風險是家長最大的疑慮。系統性回顧顯示,夜戴 OK 鏡的微生物性角膜炎風險約 7.7-13.9 / 萬人年,跟夜戴軟式隱形眼鏡相似。重點是：

• 每天用無菌沖洗液清潔,不要用自來水。
• 鏡片使用 1-1.5 年要更換,鏡盒每 3 個月換新。
• 感冒、發燒、眼睛紅停戴。
• 每 3 個月回診檢查角膜。

適合對象：近視 -1.50 至 -6.00 D、散光 < -1.50 D、8 歲以上配合度好的孩子。

迷思 5 · 「多焦點離焦鏡片（DIMS）只是噱頭，普通眼鏡就夠了」

DIMS(Defocus Incorporated Multiple Segments)鏡片由香港理工大學開發，商品名為 MyoSmart（豪雅 / Hoya)。原理：中央正常區域提供清晰視覺，周圍密布數百個 + 3.50 D 微透鏡,讓周邊視網膜接收「近視性離焦」訊號，抑制眼軸生長。

2020 年 Lam CSY 等人在 British Journal of Ophthalmology 發表的 2 年 RCT(n=160,8-13 歲）結果：

• DIMS 組近視進展 -0.41 D vs 普通鏡片組 -0.85 D（減緩 52%)
• 眼軸增長 0.21 mm vs 0.55 mm（減緩 62%)
• 2023 年 6 年延伸資料（同期 2/3 受試者）顯示效果持續

優點：無侵入性、孩子最容易配合（就跟戴普通眼鏡一樣）。缺點：價格較高，醫院實際開價約 NT$ 20,000–30,000 / 副（視框架材質、鍍膜與通路而定）;加上每 1–2 年需隨度數變化更換，是所有非藥物介入中累計花費最高的一條路。可作為單一治療，或搭配阿托品做組合療法。其他類似產品：HAL 鏡片（Highly Aspherical Lenslets, Essilor Stellest)、CARE / DOT 鏡片。

迷思 6 · 「重複式低能量紅光治療（RLRL)— 安全嗎？台灣有嗎?」

重複式低能量紅光治療（Repeated Low-Level Red-Light Therapy, RLRL)使用 650 nm 紅光，每天 2 次、每次 3 分鐘照射。Jiang Y 等人 2022 年發表在 Ophthalmology 的多中心 RCT(n=246,8-13 歲）顯示：

• RLRL 組眼軸增長 -0.06 mm（縮短）vs 對照組 +0.34 mm
• 近視度數變化 +0.17 D vs -0.49 D
• 整體近視控制效果 69-88%

但有幾項重要疑慮:

• 2024 年 JAMA Ophthalmology 報告:1 例 12 歲女童 RLRL 使用後出現急性黃斑部光損傷,部分視力恢復但中央暗點殘留。
• 長期（>5 年）安全性資料缺乏，尤其視網膜光毒性累積問題。
• 停止治療後快速反彈（>30%)。
• FDA 尚未核准用於近視控制；歐盟 CE 認證僅作為「視覺訓練」。

目前主流眼科建議：不作為第一線治療,需審慎評估、密切追蹤眼底，優先嘗試已有 10 年以上長期安全資料的阿托品或 OK 鏡。

迷思 7 · 「戶外活動跟近視沒關係吧?」

戶外活動預防近視的證據已經非常充分：

• He M 等人 2015 年發表在 JAMA 的廣州 RCT(n=1903 兒童）:每天多 40 分鐘戶外活動，3 年內新發近視率從 39.5% 降至 30.4%。
• 台灣 Wu PC 等人 2013、2020 年系列研究：推動「下課教室淨空、強迫到戶外」政策，新發近視率明顯下降。
• 劑量反應關係：戶外時間每增加 1 小時/週，近視風險降低 ~2%。

機轉假說（尚未完全確定）:

• 光照刺激視網膜釋放多巴胺 — 抑制眼軸生長
• 遠距離視覺 — 減少近距離調節需求
• 瞳孔縮小、景深增加 — 減少視網膜離焦

實務建議：每天累積 2 小時以上戶外時間（陰天也算），學齡前最關鍵。重點是「到戶外」，不是「運動」 — 戶外散步、戶外閱讀都行，只要在自然光下。

迷思 8 · 「近視控制是一輩子的事嗎？幾歲可以停?」

近視控制治療的「終點」並非固定年齡，而是近視進展自然停止的時間點。一般時間軸：

停藥前建議：

• 確認近視 連續 12 個月變化 < 0.50 D。
• 若用阿托品，可逐步降階(0.05% → 0.025% → 0.01% → 停），每 3-6 個月減一階，觀察是否反彈。
• 若用 OK 鏡，先停一兩週觀察度數變化。

停藥後仍要每年追蹤，尤其高度近視（>500 度）族群，終身需監測視網膜健康。

台灣健保給付規定（民國 115 年 4 月版）

2023 年起 低劑量阿托品納入健保 是兒童近視控制的重要進展。三大主要方法的現行給付狀況：

實務建議：

• 阿托品改成健保有給付後，第一線就可以由眼科醫師依規定開立健保處方，不需自費。具體適合與否、濃度（0.01% vs 0.05% 視臨床判斷）、是否合併其他方法，請以眼科醫師判斷為準
• DIMS、OK 鏡、RLRL 仍需自費——家長與醫師討論時可一併評估費用負擔與長期使用可行性
• 健保給付規定隨時間更新，本文以民國 115 年 4 月版為準，最新版本請以健保署公告為主

* 來源：衛福部健保署《全民健康保險藥品給付規定》民國 115 年 4 月版，第 14 章「眼科用藥」14.9.6「Atropine sulfate 0.1 mg/mL 眼用製劑」。

家長可以做的 5 件事

學齡前（6 歲前）就出現近視、家長有高度近視史、進展速度 > 0.75 D / 年 — 這三類屬高風險，建議盡早諮詢眼科專科醫師討論主動介入策略。

主要參考文獻

1. Yam JC, et al. Low-Concentration Atropine for Myopia Progression (LAMP) Study: A Randomized, Double-Blinded, Placebo-Controlled Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control. Ophthalmology. 2019;126(1):113-124.
2. Yam JC, et al. Two-Year Clinical Trial of the Low-Concentration Atropine for Myopia Progression (LAMP) Study: Phase 2 Report. Ophthalmology. 2020;127(7):910-919.
3. Yam JC, et al. Three-Year Clinical Trial of LAMP Study: Continued Versus Washout: Phase 3 Report. Ophthalmology. 2022;129(3):308-321.
4. Chia A, et al. Atropine for the Treatment of Childhood Myopia: Safety and Efficacy of 0.5%, 0.1%, and 0.01% Doses (ATOM2). Ophthalmology. 2012;119(2):347-354.
5. Lam CSY, et al. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial. Br J Ophthalmol. 2020;104(3):363-368.
6. Jiang Y, et al. Effect of Repeated Low-Level Red-Light Therapy in Myopia Control in Children: A Multicenter Randomized Controlled Trial. Ophthalmology. 2022;129(5):509-519.
7. He M, et al. Effect of Time Spent Outdoors at School on the Development of Myopia Among Children in China: A Randomized Clinical Trial. JAMA. 2015;314(11):1142-1148.
8. Wu PC, et al. Outdoor Activity during Class Recess Reduces Myopia Onset and Progression in School Children. Ophthalmology. 2013;120(5):1080-1085.
9. International Myopia Institute (IMI). Clinical Management Guidelines Report. Invest Ophthalmol Vis Sci. 2021/2023 White Papers.

Myth 1 · "Myopia is just blurry vision; LASIK fixes it later"

Myopia is fundamentally excessive axial elongation (>24 mm). The lengthened eye stretches the retina thinner and may produce breaks. Even after LASIK / SMILE reshapes the cornea, axial length does not shorten — all complications of "too long an eyeball" remain.

Adult complications of high myopia (≥−5.00 D / axial length ≥26 mm):

• Retinal detachment — 5–10× increased risk
• Glaucoma — 2–3× increased risk
• Myopic maculopathy — leading cause of irreversible blindness in Asia
• Cataract — onset 5–10 years earlier

The goal of pediatric myopia control isn't "clear vision" — it's keeping final adult refractive error below −5.00 D to reduce lifetime blindness risk.

Myth 2 · "Pseudomyopia just needs rest, no doctor visit"

Pseudomyopia is transient ciliary spasm from prolonged near work — temporarily excessive accommodation makes distance blurry, but resolves when the muscle relaxes. Axial myopia is true elongation of the eyeball — irreversible.

The two look identical externally — both manifest as "distance blur." The only reliable distinction is cycloplegic refraction, typically with 1% cyclopentolate, allowing the ciliary muscle to fully relax before refracting. If pre/post-cycloplegia refraction differs significantly → pseudomyopia predominates; if cycloplegic refraction still shows myopia → axial myopia is established.

First report of distance blur warrants immediate evaluation, not observation. Even pseudomyopia signals chronic ocular strain — without intervention it quickly becomes axial myopia. Taiwan's Ministry of Health recommends annual full ophthalmic exam (including cycloplegic refraction) for school-age children.

Myth 3 · "Low-dose atropine: 0.01% vs 0.05% — which is better?"

The 2019 Hong Kong LAMP Study (Low-concentration Atropine for Myopia Progression, Yam JC et al, Ophthalmology) randomized 438 Chinese children aged 4–12 to three concentrations of low-dose atropine. Years 2–3 follow-up reports came in 2020–2022. Key findings:

Practical interpretation:

• Fast progressors (>0.50 D/year) → start at 0.05%; step down if photophobia is intolerable.
• Slow progressors / preschool → may start at 0.025% or 0.01%.
• Rebound on cessation — ATOM2 showed high concentrations (0.5%) had large rebound; 0.01% had the smallest. LAMP year-3 data showed 0.05% and 0.025% rebound was also mild.

Most ophthalmologists today start at 0.05% with photo-protective sunglasses for glare.

Myth 4 · "Ortho-K damages the cornea and causes infection"

Orthokeratology (Ortho-K) uses high-Dk gas-permeable rigid lenses worn overnight to temporarily flatten the central cornea, allowing clear unaided daytime vision. Studies show 40–50% slowing of myopia progression — mechanism is altered peripheral retinal defocus signal.

Infection risk is parents' biggest concern. Systematic review reports microbial keratitis at 7.7–13.9 / 10,000 person-years for overnight Ortho-K — similar to overnight soft-lens wear. Key safeguards:

• Daily cleaning with sterile solution, never tap water.
• Replace lenses every 1–1.5 years; cases every 3 months.
• Stop wearing during cold, fever, or eye redness.
• Cornea check every 3 months.

Ideal candidates: −1.50 to −6.00 D myopia, astigmatism < −1.50 D, age ≥8 with good compliance.

Myth 5 · "DIMS lenses are just marketing — regular glasses work just as well"

DIMS (Defocus Incorporated Multiple Segments) lenses, developed at Hong Kong Polytechnic University and marketed as MyoSmart (Hoya), have a clear central zone surrounded by hundreds of +3.50 D microlenslets producing myopic defocus on the peripheral retina, suppressing axial elongation.

The 2020 Lam CSY et al 2-year RCT (n=160, ages 8–13, Br J Ophthalmol):

• DIMS group myopia progression: −0.41 D vs control −0.85 D (52% slowing)
• Axial elongation: 0.21 mm vs 0.55 mm (62% slowing)
• 2023 6-year extension data confirmed sustained efficacy

Advantages: non-invasive, easiest compliance (worn like any glasses). Disadvantage: cost — hospital pricing in Taiwan is typically NT$ 20,000–30,000 / pair depending on frame and coatings; plus replacement every 1–2 years as the prescription changes makes this the most expensive non-pharmacological option over time. May be used as monotherapy or combined with atropine. Similar products: HAL lenses (Highly Aspherical Lenslets, Essilor Stellest), CARE / DOT lenses.

Myth 6 · "Repeated Low-Level Red Light therapy (RLRL) — is it safe?"

Repeated Low-Level Red-Light Therapy (RLRL) uses 650 nm light, 3 minutes twice daily. Jiang Y et al's 2022 multicenter RCT (n=246, ages 8–13, Ophthalmology) reported:

• RLRL axial-length change: −0.06 mm (shortening) vs control +0.34 mm
• Refractive change: +0.17 D vs −0.49 D
• Overall myopia control efficacy: 69–88%

However, important concerns:

• 2024 JAMA Ophthalmology case report: a 12-year-old developed acute macular phototoxicity after RLRL use, with partial recovery but residual scotoma.
• Long-term (>5 year) safety data lacking, especially regarding cumulative retinal phototoxicity.
• Rapid rebound after cessation (>30%).
• Not FDA-approved for myopia control; EU CE-marked only as "vision training."

Mainstream ophthalmologic recommendation: not first-line; cautious case selection with close fundus follow-up; prefer atropine or Ortho-K with >10 years of long-term safety data.

Myth 7 · "Outdoor time has nothing to do with myopia, right?"

Evidence is robust:

• He M et al's 2015 Guangzhou JAMA RCT (n=1903 children): adding 40 min/day outdoor recess reduced 3-year myopia incidence from 39.5% to 30.4%.
• Wu PC et al's Taiwanese 2013/2020 studies: mandated outdoor recess significantly lowered new myopia incidence at the population level.
• Dose-response: each additional hour outdoors per week reduces myopia risk ~2%.

Mechanistic hypotheses (not fully proven):

• Light triggers retinal dopamine release — inhibits axial elongation
• Distant viewing — reduces accommodative demand
• Pupil constriction, increased depth of field — reduces retinal defocus

Practical advice: ≥2 hours outdoors daily (cloudy days count too) — most critical pre-school. Key is "being outdoors," not "exercise" — outdoor walking, outdoor reading both qualify, as long as in natural light.

Myth 8 · "Is myopia control lifelong? When can we stop?"

The endpoint isn't a fixed age — it's when myopia naturally plateaus. Typical timeline:

Before stopping:

• Confirm <0.50 D change over 12 consecutive months.
• For atropine, step down gradually (0.05% → 0.025% → 0.01% → off), 3–6 months per step, watch for rebound.
• For Ortho-K, suspend wear for 1–2 weeks and recheck.

Continue annual follow-up after cessation, especially for high myopia (>−5.00 D) — lifelong retinal monitoring is required.

5 things parents can do

Three high-risk groups should consult an ophthalmologist early about active intervention: onset before age 6, parental high myopia, progression >0.75 D/year.

Key references

1. Yam JC, et al. Low-Concentration Atropine for Myopia Progression (LAMP) Study. Ophthalmology. 2019;126(1):113-124.
2. Yam JC, et al. LAMP Study Phase 2 Report. Ophthalmology. 2020;127(7):910-919.
3. Yam JC, et al. LAMP Study Phase 3 — Continued vs Washout. Ophthalmology. 2022;129(3):308-321.
4. Chia A, et al. Atropine for the Treatment of Childhood Myopia (ATOM2). Ophthalmology. 2012;119(2):347-354.
5. Lam CSY, et al. DIMS spectacle lenses slow myopia progression: 2-year RCT. Br J Ophthalmol. 2020;104(3):363-368.
6. Jiang Y, et al. Repeated Low-Level Red-Light Therapy in Myopia Control. Ophthalmology. 2022;129(5):509-519.
7. He M, et al. Outdoor Time and Myopia Development in Children: RCT. JAMA. 2015;314(11):1142-1148.
8. Wu PC, et al. Outdoor Activity during Class Recess Reduces Myopia. Ophthalmology. 2013;120(5):1080-1085.
9. International Myopia Institute (IMI). Clinical Management Guidelines White Papers. Invest Ophthalmol Vis Sci. 2021/2023.